1Mês·

Share assessment

How do you do?

Here are a few stocks that I currently have on my watchlist. I have already bought a few tranches.

$TGT (+1,36%)
$PEP (+0,31%)
$NOVO B (-2,62%)
$UPS (+1,19%)

I think they are all quality companies and they also pay a dividend.

Novo Nordisk is possibly associated with more growth and the other three stocks are rather boring. However, I think the demand for the products and services will definitely not decrease.

I would be interested to know what you think of the companies mentioned. Do you have any of them on your watchlist, are you invested or do you want to get in? 😊👍🏻

12 Comentários

D.S.@Cato_Bamboo

1Mês

At $NOVO B you actually have "more" growth, unfortunately in the wrong direction........... I liquidated 50% of my position yesterday.

•

Utilizador eliminado

1Mês

O comentário foi eliminado

D.S.@Cato_Bamboo

1Mês

@Thommy98 Never 👎

•

Homer@Simpson

1Mês

If a share is not included in the Ultimate Homer, then I don't think much of it 😁

•

Earnus@Earnus

1Mês

@Marcelxy As you have already done, I would tend to go to $NOVO B for the companies presented. To put it bluntly: Diabetes and obesity will continue to exist. I personally found the sell-off after the last study results too exaggerated. In my opinion, this could just as quickly swing in the other direction. You also have to keep an eye on the cooperation with $HIMS.

Of course, $NOVO B is not doing so well at the moment, but there are always new opportunities to buy. In any case, you have to be patient.

•

Utilizador eliminado

1Mês

O comentário foi eliminado

Earnus@Earnus

1Mês

@Seebi I understand your point of view, but I actually see it somewhat differently. The biggest competitor of $NOVO B is $LLY - this applies to the diabetes division and slimming products. $PFE has been discontinued, at least in this market phase. Have I forgotten another company? I'm leaving out $HIMS for now, as they were only allowed to help out temporarily on the US market due to a bottleneck.

The sell-off at $NOVO B is mainly due to the 'weak' study results of a new weight loss product. Here, too, the efficacy hardly differed from that of $LLY. Now one can say that this speaks for $LLY. However, research will continue and for this reason I see a good risk/reward potential at the current prices. The figures for $NOVO B
are still intact and the diabetes division is also doing well.

If anything, I see geopolitical tensions as a greater risk, as the US market for $NOVO B is not unexciting.
It also depends on the purchase price - the share price fluctuates between just under €70 and €85. If you're not planning for the long term, that's also an opportunity.

•

Utilizador eliminado

1Mês

O comentário foi eliminado

Earnus@Earnus

1Mês

@Seebi I respect your opinion. But in general, anyone investing in the pharmaceutical industry should always be aware of the increased volatility anyway - but that also applies to the stock market. I stand by my view that $NOVO B still offers the greatest potential in the above selection. The only biggest risk for me is the sales market in the USA and possible regulations by Trump or his congenial health minister. But when it comes to investing, everyone is ultimately allowed to follow their own strategy. Nevertheless - and I mean this seriously - thank you for your detailed approach.

•

Tenbagger2024@Tenbagger2024

1Mês

These four companies come from very different sectors. Novo also comes from Europe. You should also look at which sector and which country is still underweight in your portfolio.

•

finanzperpetuum@finanzperpetuum

1Mês

Novo stood at around €28 in Jan 21. Wegovy was approved in 2022 and until then it wasn't a chip store either. So in 4 years as of today, we have seen an annual return of around 25%, which is not too bad. The peak was just a bit too much of a good thing. At some point you have to take a look at the valuation.

•